Aldebaran Capital LLC Increases Holdings in ESSA Pharma Inc. $EPIX

Key Points

• Aldebaran Capital LLC increased its holdings in ESSA Pharma Inc. by 43.2% in Q1, now owning 569,294 shares worth approximately $899,000.
• ESSA Pharma reported a Q2 EPS of ($0.09), surpassing estimates and with analysts predicting an average EPS of ($0.42) for the current year.
• Institutional investors own about 75.12% of ESSA Pharma, indicating strong interest from hedge funds in the company.

Aldebaran Capital LLC grew its holdings in ESSA Pharma Inc. (NASDAQ:EPIX - Free Report) TSE: EPI by 43.2% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 569,294 shares of the company's stock after buying an additional 171,771 shares during the quarter. ESSA Pharma makes up about 0.9% of Aldebaran Capital LLC's investment portfolio, making the stock its 23rd largest holding. Aldebaran Capital LLC owned approximately 1.28% of ESSA Pharma worth $899,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Bank of America Corp DE lifted its stake in shares of ESSA Pharma by 10,153,775.0% in the 4th quarter. Bank of America Corp DE now owns 812,310 shares of the company's stock valued at $1,454,000 after purchasing an additional 812,302 shares during the period. Two Sigma Investments LP purchased a new position in shares of ESSA Pharma in the 4th quarter valued at approximately $378,000. Jane Street Group LLC purchased a new position in shares of ESSA Pharma in the 4th quarter valued at approximately $82,000. Cubist Systematic Strategies LLC purchased a new position in shares of ESSA Pharma in the 4th quarter valued at approximately $47,000. Finally, Squarepoint Ops LLC purchased a new position in shares of ESSA Pharma in the 4th quarter valued at approximately $26,000. Hedge funds and other institutional investors own 75.12% of the company's stock.

ESSA Pharma Stock Performance

Shares of EPIX traded down $0.0050 on Thursday, reaching $1.9250. The stock had a trading volume of 348,680 shares, compared to its average volume of 225,433. The firm has a market capitalization of $91.07 million, a price-to-earnings ratio of -3.44 and a beta of 1.55. The company has a 50-day simple moving average of $1.81 and a 200-day simple moving average of $1.72. ESSA Pharma Inc. has a 12-month low of $1.40 and a 12-month high of $7.88.

ESSA Pharma (NASDAQ:EPIX - Get Free Report) TSE: EPI last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.17) by $0.08. On average, analysts expect that ESSA Pharma Inc. will post -0.42 EPS for the current fiscal year.

ESSA Pharma Announces Dividend

The business also recently disclosed a -- dividend, which will be paid on Friday, August 22nd. Shareholders of record on Tuesday, August 19th will be paid a dividend of $1.69 per share. The ex-dividend date is Monday, August 25th.

About ESSA Pharma

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.